Chemokine-scFv DNA vaccines elicit protective immunity in a myeloma and a lymphoma model. CD8⁺ T cells are important for protection. BALB/c mice were injected intramuscularly with 50 μg chemokine-scFv plasmids, followed by electroporation. Fourteen days later, immunized mice were challenged with (A) 1.3 × 10⁵ MOPC315 myeloma cells or (B) 1.2 × 10⁵ A20 B cell lymphoma cells subcutaneously. A tumor of 3 mm or larger was scored as tumor take. There were 10 mice in each group. *P < .05, when compared with NaCl. †P < .05, when dimeric MIP-1α hF_v^{315 (or A20)} were compared with monomeric MIP-1α F_v^{315 (or A20)}. (C,D) Requirement of T-cell subsets for protective immunity. Mice were immunized with 50 μg plasmids, repetitiously treated with anti-CD8 mAb, anti-CD4 mAb, anti–I-E^d mAb, or isotype-matched rat IgG from day 12, and injected with MOPC315 (C) and A20 (D) tumor cells. A significant reduction (P < .05), when compared with MIP-1α hF_v^{315 (or A20)} = isotype control, is marked by an asterisk. (E) BALB/c mice injected with 100 μg purified chemokine-scFv fusion proteins in PBS were injected intraperitoneally and challenged 14 days later with 1.3 × 10⁵ MOPC315 myeloma cells. *P < .05 compared with nontargeted chemokine-scFv³¹⁵.